

DRAFT Medical Coverage Policy | Gene Expression Profiling for Cutaneous Melanoma



EFFECTIVE DATE: 07|01|2024

POLICY LAST REVIEWED: 04|17|2024

OVERVIEW

Laboratory tests have been developed that detect the expression of different genes in pigmented lesions or melanoma tumor tissue. Test results may help providers and patients decide whether to biopsy suspicious pigmented lesions, aid in diagnosis of lesions with indeterminate histopathologic findings or determine whether to perform sentinel lymph node biopsy in patients diagnosed with stage I or II cutaneous melanoma.

The following tests are addressed in this policy:

- DecisionDx-Melanoma (Castle Biosciences) CPT code 81529
- Pigmented Lesion Assay (DermTech) CPT code 0089U
- myPath Melanoma (Castle Biosciences) CPT code 0090U

MEDICAL CRITERIA

Medicare Advantage Plans and Commercial Products

DecisionDx Melanoma - 81529

DecisionDx Melanoma may be considered medically necessary when the following criteria are met:

- Patients diagnosed with cutaneous melanoma tumors with clinically negative sentinel node basins who are being considered for SLNB to determine eligibility for adjuvant therapy, and 1 or 2 below:
 1. Cutaneous melanoma ≥ 0.3 mm in Breslow thickness **without distant metastases** where additional information beyond anatomic and pathologic staging:
 - Will influence the decision to perform Sentinel Lymph Node Biopsy (T1-T2 only)
 - Will aid in the determination of appropriate adjuvant therapy
 2. Cutaneous melanoma < 0.3 mm in Breslow thickness being considered for sentinel lymph node biopsy:
 - in whom there is significant uncertainty about the adequacy of microstaging (positive deep margin), or
 - with other adverse features (e.g. very high mitotic index $[\geq 2/\text{mm}^2]$, lymphovascular invasion, or combination of these factors)

myPath Melanoma – 0090U

myPath Melanoma may be considered medically necessary when the following criteria are met:

- The test is ordered by a board-certified dermatopathologist and;
- The lesion is considered to be a non-metastatic, melanocytic lesion that has not been previously treated, and;
- Testing is an adjunct to histopathology, as a clear distinction between a benign or malignant lesion cannot be made using clinical characteristics and histopathological features alone, and;
- The patient may be subjected to additional intervention, such as re-excision and/or sentinel lymph node biopsy, as a result of the diagnostic uncertainty, and;
- The results of the gene expression testing will be used in conjunction with the clinical evaluation, histopathological features and other diagnostic procedures to determine and/or alter the treatment plan.

PRIOR AUTHORIZATION

Medicare Advantage Plans and Commercial Products

Prior authorization is required for the following tests:

- DecisionDx-Melanoma
- myPath Melanoma

Note: Laboratories are not allowed to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician. Only the ordering physician shall be involved in the authorization, appeal or other administrative processes related to prior authorization/medical necessity.

In no circumstance shall a laboratory or a physician/provider use a representative of a laboratory or anyone with a relationship to a laboratory and/or a third party to obtain authorization on behalf of the ordering physician, to facilitate any portion of the authorization process or any subsequent appeal of a claim where the authorization process was not followed and/or a denial for clinical appropriateness was issued, including any element of the preparation of necessary documentation of clinical appropriateness. If a laboratory or a third party is found to be supporting any portion of the authorization process, BCBSRI will deem the action a violation of this policy and severe action will be taken up to and including termination from the BCBSRI provider network. If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

POLICY STATEMENT

Medicare Advantage Plans and Commercial Products

The following tests may be considered medically necessary when the medical criteria above are met:

- DecisionDx-Melanoma
- myPath Melanoma

The following test is covered:

- Pigmented Lesion Assay

Commercial Products

Some genetic testing services are not covered and a contract exclusion for any self-funded group that has excluded the expanded coverage of biomarker testing related to the state mandate, R.I.G.L. §27-19-81 described in the Biomarker Testing Mandate policy. For these groups, a list of which genetic testing services are covered with prior authorization, are not medically necessary or are not covered because they are a contract exclusion can be found in the Coding section of the Genetic Testing Services or Proprietary Laboratory Analyses policies. Please refer to the appropriate Benefit Booklet to determine whether the member's plan has customized benefit coverage. Please refer to the list of Related Policies for more information.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable laboratory benefits/coverage.

BACKGROUND

Cutaneous Melanoma

Cutaneous melanoma accounts for more than 90% of cases of melanoma. For many decades, melanoma incidence was rapidly increasing in the United States. However, recent estimates have suggested the rise may be slowing. In 2018, more than 90,000 new cases of melanoma are expected to be diagnosed and more than 9,000 people are expected to die of melanoma.

Risk Factors

Exposure to solar ultraviolet radiation is a major risk factor for melanoma. Most melanomas occur on sun-exposed skin, particularly those areas most susceptible to sunburn. Likewise, features that are associated with

an individual's sensitivity to sunlight, such as light skin pigmentation, red or blond hair, blue or green eyes, freckling tendency, and poor tanning ability are well-known risk factors for melanoma. There is also a strong association between high total body nevus counts and melanoma.

Several genes appear to contribute to melanoma predisposition such as tumor suppressor gene CDKN2A, melanocortin-1 receptor (MC1R) gene, and BAP1 variants. Individuals with either familial or sporadic melanoma have a 2 to 3 times increased risk of developing a subsequent primary melanoma. Several occupational exposures and lifestyle factors, such as body mass index and smoking, have been evaluated as possible risk factors for melanoma.

Gene Expression Profiling (GEP)

GEP measures the activity of thousands of genes simultaneously and creates a snapshot of cellular function. Data for GEP are generated by several molecular technologies including DNA microarrays that measure activity relative to previously identified genes and RNA-Seq that directly sequences and quantifies RNA molecules. Clinical applications of GEP include disease diagnosis, disease classification, prediction of drug response and prognosis.

DecisionDx-Melanoma

The DecisionDx test measures expression of 31 genes using quantitative reverse-transcription polymerase chain reaction. The test includes 28 prognostic gene targets and 3 endogenous control genes. The test is performed on standard tissue sections from an existing formalin-fixed, paraffin-embedded biopsy or wide local excision specimen. Clinically negative sentinel node basins (clinically node negative is defined as no signs of lymph node metastases, consisting of a negative physical examination and preoperative ultrasound). The DecisionDx test report provides a 'class' which stratifies tumors as class 1 or class 2. According to the sample report available on the manufacturer website: "The DecisionDx-Melanoma algorithm generates a value between 0 and 1 with a crossover point of 0.5. Subclassification (A or B) is based on proximity of this value to the crossover point."

Pigmented Lesion Assay (PLA)

The Pigmented Lesion Assay test measures expression of 6 genes (PRAME, LINC00518, CMIP, B2M, ACTB, PPIA). The PRAME (PReferentially expressed Antigenin MELanoma) gene encodes an antigen that is preferentially expressed in human melanomas, and that is not expressed in normal tissues (except testis). LINC00518 (Long Intergenic Non-protein Coding RNA518) is a regulatory RNA molecule. The other 4 genes provide normalization values.

The test is performed on skin samples of lesions at least 5 mm in diameter obtained via noninvasive, proprietary adhesive patch biopsies of a stratum corneum specimen. The test does not work on the palms of hands, soles of feet, nails, or mucous membranes, and it should not be used on bleeding or ulcerated lesions.

The Pigmented Lesion Assay test report includes 2 results. The first result is called the PLA MAGE (Melanoma Associated Gene Expression), which indicates low-risk (neither PRAME nor LINC00518 expression was detected), moderate-risk (expression of either PRAME or LINC00518 was detected), or high-risk (expression of both PRAME and LINC00518 was detected). The second result is as an algorithmic Pigmented Lesion Assay score that ranges from 0 to 100, with higher scores indicating higher suspicion of malignant disease.

myPath Melanoma

The myPath test measures expression of 23 genes using quantitative reverse-transcription polymerase chain reaction. Fourteen genes are involved in melanoma pathogenesis and are grouped into 3 components related to cell differentiation, cell signaling, and the immune response, and 9 housekeeper genes are also included. The test is performed on 5 standard tissue sections from an existing formalin-fixed, paraffin-embedded biopsy specimen.

The myPath test report includes an algorithmic myPath score ranging from -16.7 to 11.1, with higher, positive scores indicating higher suspicion of malignant disease. The myPath report also classifies these scores: -16.7 to -2.1 are “benign”; -2.0 to -0.1 are “indeterminate”; and 0.0 to +11.1 are “malignant”. The myPath test is meant as an add-on test to standard histopathology.

CODING

Medicare Advantage Plans and Commercial Products

The following CPT code(s) are covered when medical criteria above are met:

This code can be used for DecisionDx-Melanoma:

81529 Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis

This code can be used for myPath Melanoma:

0090U Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)

The following CPT code(s) are covered without authorization:

This code can be used for Pigmented Lesion Assay (PLA):

0089U Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)

RELATED POLICIES

Biomarker Testing Mandate

Genetic Testing Services

Proprietary Laboratory Analyses (PLA)

PUBLISHED

Provider Update, June 2024

Provider Update, February/July/November 2023

Provider Update, October 2021

Provider Update, November 2020

Provider Update, April 2019

REFERENCES

1. Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD): MolDX: Pigmented Lesion Assay (L38151)
2. Centers for Medicare and Medicaid Services. Local Coverage Article: Billing and Coding: MolDX: Pigmented Lesion Assay (A58052)
3. Gerami P, Alsobrook JP, Palmer TJ, Robin HS. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin. *J Am Acad Dermatol.* 2014 Aug;71(2):237-44.
4. Gerami P, Cook RW, Russell MC, Wilkinson J, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. *J Am Acad Dermatol.* 2015 May;72(5):780-5.
5. Warf MB, Flake DD, Adams D, Gutin A, et al. Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions. *Biomark Med.* 2015;9(5):407-16.
6. Hsueh EC, Schwartz TL, Lizalek JM, et al. Prospective validation of gene expression profiling in primary cutaneous melanoma. *Journal of Clinical Oncology* 34, no. 15_suppl (May 2016) 9565-9565.

7. Clarke LE, Flake DD, Busam K, et al. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. *Cancer*. 2017 Feb 15;123(4):617-628.
8. Cockerell C, Tschen J, Billings SD, Evans B, Brown K, Rock C, Clarke LE. The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions. *Per Med*. 2017 Mar;14(2):123-130
9. Cockerell CJ, Tschen J, Evans B, Bess E, Kidd J, Kolquist KA, Rock C, Clarke LE. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. *Medicine*. 2016 Oct;95(40):e4887
10. Clarke LE, Warf MB, Flake DD, Hartman AR, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. *J Cutan Pathol* 2015; 42: 244–252.
11. Ko JS, Matharoo-Ball B, Billings SD, et al. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. *Cancer Epidemiol Biomarkers Prev*; 2017;26(7); 1107–13.
12. Leachman SA, Koon SM, Korcheva VB, White KP. Assessing Genetic Expression Profiles in Melanoma Diagnosis. *Dermatol Clin* 2017;35: 537–544.
13. Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. *Curr Med Res Opin*. 2016 Sep;32(9):1599-604.
14. Farberg AS, Glazer AM, Winkelmann RR, Rigel DS. Assessing Genetic Expression Profiles in Melanoma Prognosis. *Dermatol Clin*. 2017 Oct;35(4):545-550.
15. Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. *J Am Acad Dermatol*. 2017 May;76(5):818-825.
16. Minca EC, Al-Rohil RN, Wang M, et al. Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. *Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc*. 2016;29(8):832-843.
17. Cassarino DS, Lewine N, Cole D, Wade B, Gustavsen G. Budget impact analysis of a novel gene expression assay for the diagnosis of malignant melanoma. *Journal of medical economics*. 2014;17(11):782-791.
18. National Comprehensive Cancer Network (NCCN) – Melanoma v2.2021
19. Hayes Genetic Testing Evaluation (GTE) Synopsis: DecisionDx- Melanoma
20. Renzetti M, Farma J, Handor B et al. Combined experience of two tertiary referral centers with DecisionDx-Melanoma GEP testing. In Society of Surgical Oncology Seattle, WA: 2017.
21. Fleming MD, Johnson C, Covington KR et al. Clinical impact of a 31-gene expression profile test on physician recommendations for management of melanoma patients in a prospectively tested cohort. In Society of Melanoma Research. Brisbane, Australia: 2017
22. Moody JA, Ali RF, Carbone AC et al. Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature. *Eur J Surg Oncol* 2017; 43: 270-277.
23. Wong SL, Faries MB, Kennedy EB et al. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017
24. Faries MB, Thompson JF, Cochran AJ et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. *N Engl J Med* 2017; 376: 2211-2222
25. Zager JS, Gastman BR, Leachman S et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. *BMC Cancer* 2018; 18:130
26. Hsueh EC, DeBloom JR, Lee J et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. *J Hematol Oncol* 2017; 10: 152
27. Gerami P, Cook RW, et al. Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma. *Clin Cancer Res* 2015;21:175-183.

28. Svoboda RM, Glazer AM, et al. Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma. *J Drugs Dermatol.* 2018;17(5):544-547.
29. Schuitevoerder D, Heath M, et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. *J Drugs Dermatol.* 2018;17(2):196-199.
30. Farberg AS, Glazer AM, et al. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions *J Drugs Dermatol.* 2017;16(5):428-431.
31. Dillon LD, Gadzia JE, et al. Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. *Skin* 2018;2(2):111-121.
32. Greenshaw BN, Zitelli JA, Brodland DG. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test. *Dermatol Surg* 2018;0:1-7
33. Mirsky RS, Prado G, et al. management decisions made by physician assistants and nurse practitioners in cutaneous malignant melanoma patients: Impact of a 31-gene expression profile test. *J Drugs Dermatol.* 2018;17(11):1220-1223.
34. Cook RW, Middlebrook B, et al. Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. *Diagnostic Pathology* (2018) 13:13
35. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. *Future Oncol.* 29 January 2019
36. Keller J, Schwartz TL, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. *Cancer Medicine.* 2019;1-8.
37. Gastman BR, Zager JS, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. *Head & Neck.* 2019;41:871-879.
38. Swetter S, Tsao H, Bichakjian C, et. al., America Academy of Dermatology Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol* 2019;80:208-50
39. Greenhaw BN, Covington KR, Kurley SJ, Yeniyay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML, Molecular risk prediction in cutaneous melanoma: a metaanalysis of the 31-gene expression profile prognostic test in 1,479 patients, *Journal of the American Academy of Dermatology* 2020
40. NIH, National cancer Institute. Moles to Melanoma: Recognizing the ABCDE Features. <https://moles-melanoma-tool.cancer.gov/>
41. Ferris LK, Gerami P, Skelsey MK, et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. *Melanoma Res.* 2018;28(5):478-482.
42. Ferris LK, Jansen B, Ho J, et al. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. *JAMA Dermatol.* 2017;153(7):675-680.
43. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. *J Am Acad Dermatol.* 2017;76(1):114-120 e112.
44. Yao Z, Moy R, Allen T, Jansen B. An Adhesive Patch-Based Skin Biopsy Device for Molecular Diagnostics and Skin Microbiome Studies. *J Drugs Dermatol.* 2017;16(10):979-986.
45. Local Coverage Determination (LCD):MolDX: Melanoma Risk Stratification Molecular Testing (L37750)
46. MolDX: myPath® Melanoma Assay (L37859)
47. Kwatra S.G., H.H., Semenov Y.R., Trotter S.C., Holland E., Leachman S. A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma. *J Clin Aesthet Dermatol* 2020 13, S3-S14
48. Hyams DM, Covington KR, Johnson CE, et al. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. *Future Oncol.* Feb 2021; 17(5): 517-527

DRAFT

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

